Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
38 hedge funds and large institutions have $1.25M invested in Iterum Therapeutics in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 10 closing their positions.
0.03% more ownership
Funds ownership: 0.19% → 0.21% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
7% less funds holding
Funds holding: 41 → 38 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
40% less capital invested
Capital invested by funds: $2.08M → $1.25M (-$829K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$76K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$76K |
| 3 |
Renaissance Technologies
New York
|
+$53.7K |
| 4 |
KF
Krilogy Financial
St. Louis,
Missouri
|
+$49.9K |
| 5 |
Millennium Management
New York
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$43K |
| 2 |
Franklin Resources
San Mateo,
California
|
-$31.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$18K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$10K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.36K |
ITRM Hedge Fund Activity: Q2 2022 in Review
38 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q2 2022, worth a combined $1.25M — down 40% from $2.08M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ITRM and 7 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $76K. The largest seller was Virtu Financial, cutting an estimated $43K.
- 38 institutional investors held Iterum Therapeutics (ITRM) as of Q2 2022, down from 41 in Q1 2022.
- Funds reported $1.25M of Iterum Therapeutics stock for Q2 2022, down 40% quarter-over-quarter.
- 7 funds opened new Iterum Therapeutics positions in Q2 2022 and 10 closed out, a net change of -3 holders.
- The largest Iterum Therapeutics buyer in Q2 2022 was Goldman Sachs, an estimated $76K added.
- The largest Iterum Therapeutics seller in Q2 2022 was Virtu Financial, an estimated $43K sold.
Based on aggregated 13F filings for Q2 2022.